Kos Could Launch Icatibant For Hereditary Angioedema In 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm expects to report top-line data from two ongoing Phase III studies in the third quarter.
You may also be interested in...
Dyax Loses Genzyme As DX-88 Partner, But Still Eyes 2008 Approval
Firm is yet to make a decision on whether it will find new partner or continue development on its own.
Dyax DX-88 Submission Likely Postponed For Additional Dosing Study
FDA seeks a subcutaneous dose-ranging study on the recombinant protein to treat hereditary angioedema.
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.